QRxPharma’s Moxduo Doesn’t Offer Respiratory Safety Advantage, FDA Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee briefing documents state that the fixed-dose combination of immediate-release morphine and oxycodone was not superior to either of its individual components with regard to oxygen desaturation rate.
You may also be interested in...
Tighter REMS For Zohydro ER Still Insufficient For FDA Advisory Panel
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee wants Risk Evaluation and Mitigation Strategies enhanced for all extended-release/long-acting opioids as it recommends 11-2, one abstention, against approval of Zogenix’s single-entity hydrocodone product.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.